Table of Content

1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.2.1 MARKETS COVERED 14
1.2.2 YEARS CONSIDERED FOR THE STUDY 14
1.3 CURRENCY 15
1.4 LIMITATIONS 15
1.5 STAKEHOLDERS 15

2 RESEARCH METHODOLOGY 16
2.1 SECONDARY DATA 17
2.1.1 KEY DATA FROM SECONDARY SOURCES 17
2.2 PRIMARY DATA 18
2.2.1 KEY DATA FROM PRIMARY SOURCES 19
2.3 MARKET SIZE ESTIMATION 19
2.3.1 BOTTOM-UP APPROACH 20
2.3.2 TOP-DOWN APPROACH 20
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 21
2.5 ASSUMPTIONS FOR THE STUDY 22

3 EXECUTIVE SUMMARY 23

4 PREMIUM INSIGHTS 27
4.1 HEMATO-ONCOLOGY TESTING: MARKET OVERVIEW 27
4.2 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT AND SERVICE (2018) 28
4.3 GEOGRAPHICAL SNAPSHOT OF THE HEMATO-ONCOLOGY TESTING MARKET 29

5 MARKET OVERVIEW 30
5.1 INTRODUCTION 30
5.2 MARKET DYNAMICS 30
5.2.1 DRIVERS 31
5.2.1.1 Increasing incidence of hematologic cancer 31
5.2.1.2 Increasing collaborations 32
5.2.1.3 Increasing conferences on personalized medicine 32
5.2.2 OPPORTUNITIES 33
5.2.2.1 Drug diagnostics co-development 33
5.2.2.2 Emerging markets 33
5.2.3 RESTRAINTS 34
5.2.3.1 Uncertain reimbursement scenario in different regions 34
5.2.3.2 Complex regulatory frameworks delaying the approval of new molecular diagnostic tests 35
5.2.4 CHALLENGES 36
5.2.4.1 Intellectual property rights protection issues 36

6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE 37
6.1 INTRODUCTION 38
6.2 SERVICES 39
6.2.1 RISING INCIDENCE OF HEMATOLOGIC CANCER TO INCREASE THE DEMAND FOR HEMATO-ONCOLOGY SERVICES 39
6.3 ASSAY KITS 40
6.3.1 GROWING FOCUS ON THE DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 40

7 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 42
7.1 INTRODUCTION 43
7.2 LEUKEMIA 44
7.2.1 ACUTE MYELOID LEUKEMIA 45
7.2.1.1 AML IS THE MOST COMMON ACUTE LEUKEMIA AFFECTING ADULTS 45
7.2.2 ACUTE LYMPHOCYTIC LEUKEMIA 45
7.2.2.1 North America accounted for the largest share of the ALL segment 45
7.2.3 OTHER LEUKEMIAS 46
7.3 LYMPHOMA 47
7.3.1 NON-HODGKIN LYMPHOMA 48
7.3.1.1 Non-Hodgkin lymphoma holds the largest share of the market for lymphoma 48
7.3.2 HODGKIN LYMPHOMA 48
7.3.2.1 APAC hemato-oncology testing market for Hodgkin lymphoma will grow at the highest rate 48
7.4 OTHER CANCERS 49

8 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 50
8.1 INTRODUCTION 51
8.2 PCR 52
8.2.1 PCR ACCOUNTED FOR THE LARGEST SHARE OF THE HEMATO-ONCOLOGY TESTING MARKET IN 2018 52
8.3 IHC 53
8.3.1 IHC ACCOUNTED FOR THE SECOND-LARGEST SHARE OF THE HEMATO-ONCOLOGY TESTING MARKET 53
8.4 NGS 53
8.4.1 NGS IS EXPECTED TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 53
?
8.5 CYTOGENETICS 54
8.5.1 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE OF THE CYTOGENETICS MARKET 54
8.6 OTHER TECHNOLOGIES 55

9 HEMATO-ONCOLOGY TESTING MARKET, BY END USER 56
9.1 INTRODUCTION 57
9.2 CLINICAL LABORATORIES 58
9.2.1 PRESENCE OF ROBUST INFRASTRUCTURE IS THE MAJOR DRIVING FACTOR FOR THIS SEGMENT 58
9.3 HOSPITALS 59
9.3.1 HOSPITALS ACCOUNTED FOR THE SECOND-LARGEST SHARE OF THE MARKET, BY END USER 59
9.4 ACADEMIC & RESEARCH INSTITUTES 60
9.4.1 APAC MARKET FOR ACADEMIC & RESEARCH INSTITUTES WILL GROW AT THE HIGHEST RATE 60
9.5 OTHER END USERS 60

10 HEMATO-ONCOLOGY TESTING MARKET, BY REGION 62
10.1 INTRODUCTION 63
10.2 NORTH AMERICA 64
10.2.1 US 68
10.2.1.1 The US dominates the North American hemato-oncology testing market 68
10.2.2 CANADA 71
10.2.2.1 Initiatives undertaken by healthcare authorities in the country to ensure the delivery of better public healthcare to support the growth of the hemato-oncology testing market in Canada 71
10.3 EUROPE 74
10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET GROWTH 74
10.4 ASIA PACIFIC 77
10.4.1 ASIA PACIFIC MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 77
10.5 REST OF THE WORLD 81

11 COMPETITIVE LANDSCAPE 84
11.1 OVERVIEW 84
11.2 MARKET RANKING ANALYSIS, 2017 85
11.3 KEY STRATEGIES 86
11.3.1 PRODUCT LAUNCHES & APPROVALS, 2016–2019 86
11.3.2 EXPANSIONS, 2016–2019 86
11.3.3 PARTNERSHIPS AND COLLABORATIONS, 2016–2019 86
11.3.4 ACQUISITIONS, 2016–2019 87

12 COMPANY PROFILES 88
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 F. HOFFMAN-LA ROCHE LTD. 88
12.2 ABBOTT LABORATORIES 90
12.3 QIAGEN N.V. 92
12.4 THERMO FISHER SCIENTIFIC, INC. 94
12.5 ILLUMINA, INC. 96
12.6 BIO-RAD LABORATORIES, INC. 98
12.7 MOLECULARMD (SUBSIDIARY OF ICON PLC) 100
12.8 ARCHERDX, INC. 102
12.9 ARUP LABORATORIES INC. 103
12.10 ASURAGEN, INC. 104
12.11 INVIVOSCRIBE, INC. 105
12.12 ADAPTIVE BIOTECHNOLOGIES. 107
*Details on Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

13 APPENDIX 109
13.1 INSIGHTS OF INDUSTRY EXPERTS 109
13.2 DISCUSSION GUIDE 110
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 113
13.4 AVAILABLE CUSTOMIZATIONS 115
13.5 RELATED REPORTS 115
13.6 AUTHOR DETAILS 116



List of Figures



FIGURE 1 HEMATO-ONCOLOGY TESTING MARKET 14
FIGURE 2 RESEARCH DESIGN 16
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 18
FIGURE 4 HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH 20
FIGURE 5 HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH 20
FIGURE 6 DATA TRIANGULATION METHODOLOGY 21
FIGURE 7 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT AND SERVICE 2019 VS. 2024 (USD MILLION) 23
FIGURE 8 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 2019 VS. 2024 (USD MILLION) 24
FIGURE 9 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 2019 VS. 2024 (USD MILLION) 24
FIGURE 10 HEMATO-ONCOLOGY TESTING MARKET, BY END USER 2019 VS. 2024 (USD MILLION) 25
FIGURE 11 HEMATO-ONCOLOGY TESTING MARKET, BY REGION 2019 VS. 2024 (USD MILLION) 25
FIGURE 12 INCREASING INCIDENCE OF HEMATOLOGY CANCER TO DRIVE MARKET GROWTH 27
FIGURE 13 SERVICES TO DOMINATE THE NORTH AMERICAN MARKET IN 2018 28
FIGURE 14 NORTH AMERICA ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2018 29
FIGURE 15 HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES 30
FIGURE 16 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2019 VS. 2024) 38
FIGURE 17 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE (2019 VS. 2024) 43
FIGURE 18 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY (2019 VS. 2024) 51
FIGURE 19 HEMATO-ONCOLOGY TESTING MARKET, BY END USER (2019 VS. 2024) 57
FIGURE 20 HEMATO-ONCOLOGY TESTING MARKET, BY REGION (2019 VS. 2024) 63
FIGURE 21 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT 64
FIGURE 22 KEY DEVELOPMENTS IN THE HEMATO-ONCOLOGY TESTING MARKET FROM
2016 TO 2018 84
FIGURE 23 ROCHE DIAGNOSTIC: COMPANY SNAPSHOT (2018) 88
FIGURE 24 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2018) 90
FIGURE 25 QIAGEN N.V.: COMPANY SNAPSHOT (2018) 92
FIGURE 26 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2018) 94
FIGURE 27 ILLUMINA, INC.: COMPANY SNAPSHOT (2018) 96
FIGURE 28 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2018) 98
FIGURE 29 ICON PLC: COMPANY SNAPSHOT (2018) 100

 

List of Tables



TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2018–2040 31
TABLE 2 GERIATRIC POPULATION, BY REGION, 2015 VS. 2030 31
TABLE 3 HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2009 VS. 2016 33
TABLE 4 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2018 VS. 2030 34
TABLE 5 REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS 34
TABLE 6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE 2017–2024 (USD MILLION) 38
TABLE 7 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION 2017–2024 (USD MILLION) 39
TABLE 8 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE 2017–2024 (USD MILLION) 40
TABLE 9 HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION 2017–2024 (USD MILLION) 41
TABLE 10 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 2017–2024 (USD MILLION) 43
TABLE 11 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION 2017–2024 (USD MILLION) 44
TABLE 12 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE 2017–2024 (USD MILLION) 44
TABLE 13 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA BY REGION, 2017–2024 (USD MILLION) 45
TABLE 14 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA BY REGION, 2017–2024 (USD MILLION) 46
TABLE 15 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2017–2024 (USD MILLION) 46
TABLE 16 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION 2017–2024 (USD MILLION) 47
TABLE 17 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE 2017–2024 (USD MILLION) 47
TABLE 18 HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA BY REGION, 2017–2024 (USD MILLION) 48
TABLE 19 HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA BY REGION, 2017–2024 (USD MILLION) 49
TABLE 20 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION 2017–2024 (USD MILLION) 49
TABLE 21 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 51
TABLE 22 HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION 2017–2024 (USD MILLION) 52
TABLE 23 HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION 2017–2024 (USD MILLION) 53
TABLE 24 HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION 2017–2024 (USD MILLION) 54
TABLE 25 HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION 2017–2024 (USD MILLION) 55
TABLE 26 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2017–2024 (USD MILLION) 55
TABLE 27 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2017–2024 (USD MILLION) 57
TABLE 28 HEMATO-ONCOLOGY TESTING MARKET FOR REFERENCE LABORATORIES BY REGION, 2017–2024 (USD MILLION) 58
TABLE 29 HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION 2017–2024 (USD MILLION) 59
TABLE 30 HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2017–2024 (USD MILLION) 60
TABLE 31 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2017–2024 (USD MILLION) 61
TABLE 32 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2017–2024 (USD MILLION) 63
TABLE 33 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY 2017–2024 (USD MILLION) 65
TABLE 34 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION) 65
TABLE 35 NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2017–2024 (USD MILLION) 65
TABLE 36 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION) 66
TABLE 37 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA BY TYPE, 2017–2024 (USD MILLION) 66
TABLE 38 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA BY TYPE, 2017–2024 (USD MILLION) 66
TABLE 39 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION) 67
TABLE 40 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER 2017–2024 (USD MILLION) 67
TABLE 41 US: LEUKEMIA AT A GLANCE 68
TABLE 42 US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE 2017–2024 (USD MILLION) 69
TABLE 43 US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 2017–2024 (USD MILLION) 69
TABLE 44 US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE 2017–2024 (USD MILLION) 69
TABLE 45 US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE 2017–2024 (USD MILLION) 70
TABLE 46 US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 70
TABLE 47 US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER 2017–2024 (USD MILLION) 70
TABLE 48 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE 2017–2024 (USD MILLION) 71
TABLE 49 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 2017–2024 (USD MILLION) 72
TABLE 50 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE 2017–2024 (USD MILLION) 72
TABLE 51 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA BY TYPE, 2017–2024 (USD MILLION) 72
TABLE 52 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 73
TABLE 53 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER 2017–2024 (USD MILLION) 73
TABLE 54 INCIDENCE OF LEUKEMIA, BY COUNTRY, 2018–2035 74
TABLE 55 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE 2017–2024 (USD MILLION) 74
TABLE 56 EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE 2017–2024 (USD MILLION) 75
TABLE 57 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 2017–2024 (USD MILLION) 75
TABLE 58 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE 2017–2024 (USD MILLION) 75
TABLE 59 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION) 76
TABLE 60 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 76
TABLE 61 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER 2017–2024 (USD MILLION) 77
TABLE 62 GERIATRIC POPULATION, BY COUNTRY, 2015 VS. 2030 77
TABLE 63 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2017–2024 (USD MILLION) 78
TABLE 64 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE 2017–2024 (USD MILLION) 78
TABLE 65 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 2017–2024 (USD MILLION) 79
TABLE 66 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2017–2024 (USD MILLION) 79
TABLE 67 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2017–2024 (USD MILLION) 79
TABLE 68 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 80
TABLE 69 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER 2017–2024 (USD MILLION) 80
TABLE 70 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE 2017–2024 (USD MILLION) 81
TABLE 71 ROW: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE 2017–2024 (USD MILLION) 81
TABLE 72 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 2017–2024 (USD MILLION) 82
TABLE 73 ROW: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE 2017–2024 (USD MILLION) 82
TABLE 74 ROW: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE 2017–2024 (USD MILLION) 82
TABLE 75 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 2017–2024 (USD MILLION) 83
TABLE 76 ROW: HEMATO-ONCOLOGY TESTING MARKET, BY END USER 2017–2024 (USD MILLION) 83
TABLE 77 RANKING OF COMPANIES IN THE HEMATO-ONCOLOGY TESTING MARKET, 2018 85